Stay updated on Pembrolizumab in Hypermutation Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page
- Check4 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4; no substantive updates to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page footer now shows Revision: v3.3.3, and the previous Revision: v3.3.2 and the HHS Vulnerability Disclosure text have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedThe changes update the Publications section wording to indicate that PubMed-listed publications are automatically populated from PubMed, and note the revision version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedA government funding/status notice at the top of the page was removed. This change does not affect the study content, eligibility criteria, or results of the trial. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check76 days agoChange DetectedThe updated screenshots show cosmetic UI adjustments with no changes to core trial information (status, enrollment, eligibility, outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check105 days agoChange DetectedAdds a current operating-status notice, a verified status entry with a date, and a new revision (v3.2.0); removes the old status and previous revision (v3.1.0).SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.